Ascletis Pharma Inc.
HKEX:1672.HK
1.04 (HKD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 56.596 | 54.09 | 76.876 | 35.001 | 173.443 | 166.325 | 53.202 | 32.976 |
| Cost of Revenue
| 30.606 | 78.782 | 37.703 | 58.498 | 49.16 | 12.379 | 0 | 0 |
| Gross Profit
| 25.99 | -24.692 | 39.173 | -23.497 | 124.283 | 153.946 | 53.202 | 32.976 |
| Gross Profit Ratio
| 0.459 | -0.456 | 0.51 | -0.671 | 0.717 | 0.926 | 1 | 1 |
| Reseach & Development Expenses
| 216.781 | 267.102 | 213.32 | 109.099 | 125.962 | 143.452 | 114.325 | 62.689 |
| General & Administrative Expenses
| 62.576 | 15.429 | 16.491 | 20.437 | 24.543 | 85.789 | 37.477 | 15.044 |
| Selling & Marketing Expenses
| 0.387 | 16.985 | 20.872 | 27.356 | 100.5 | 58.633 | 0 | 0 |
| SG&A
| 62.963 | 32.414 | 37.363 | 47.793 | 125.043 | 144.422 | 37.477 | 15.044 |
| Other Expenses
| -2.039 | 15.421 | -27.427 | -27.453 | -25.45 | -10.755 | -0.071 | -0.013 |
| Operating Expenses
| 326.198 | 314.937 | 223.256 | 129.439 | 225.555 | 214.856 | 120.389 | 75.726 |
| Operating Income
| -308.946 | -262.817 | -195.896 | -156.429 | -36.44 | -60.91 | -67.187 | -42.75 |
| Operating Income Ratio
| -5.459 | -4.859 | -2.548 | -4.469 | -0.21 | -0.366 | -1.263 | -1.296 |
| Total Other Income Expenses Net
| 164.231 | -52.026 | -3.121 | -52.812 | -59.529 | 41.04 | -13.254 | 10.877 |
| Income Before Tax
| -144.715 | -314.843 | -199.017 | -209.241 | -95.969 | -19.87 | -80.441 | -31.873 |
| Income Before Tax Ratio
| -2.557 | -5.821 | -2.589 | -5.978 | -0.553 | -0.119 | -1.512 | -0.967 |
| Income Tax Expense
| 95.401 | 51.869 | 3.121 | 52.812 | 59.529 | -0.125 | 6.49 | -3.516 |
| Net Income
| -144.715 | -366.712 | -202.138 | -262.053 | -155.498 | -7.258 | -53.935 | -26.807 |
| Net Income Ratio
| -2.557 | -6.78 | -2.629 | -7.487 | -0.897 | -0.044 | -1.014 | -0.813 |
| EPS
| -0.13 | -0.34 | -0.18 | -0.25 | -0.15 | -0.008 | -0.048 | -0.024 |
| EPS Diluted
| -0.13 | -0.34 | -0.18 | -0.25 | -0.15 | -0.008 | -0.048 | -0.024 |
| EBITDA
| -195.065 | -232.626 | -166.351 | -129.266 | -14.292 | -48.93 | -62.161 | -38.729 |
| EBITDA Ratio
| -3.447 | -4.301 | -2.164 | -3.693 | -0.082 | -0.294 | -1.168 | -1.174 |